Our findings that lncRNA MIR31HG stimulates GLI2 by WDR5/MLL3/P300-mediated active chromatin landscape highlight lncRNA MIR31HG as a potential target for clinical lung cancer clinic treatment (Fig. 7). This evidence concerns the gene GLI2 and lung carcinoma.